NeuroPace (NASDAQ:NPCE) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen cut shares of NeuroPace (NASDAQ:NPCE) from a hold rating to a sell rating in a report published on Saturday morning,Wall Street Zen reports.

Other equities analysts also recently issued research reports about the stock. Leerink Partners downgraded shares of NeuroPace from an “outperform” rating to a “market perform” rating and set a $7.00 price target for the company. in a research note on Friday. KeyCorp reduced their price objective on NeuroPace from $18.00 to $14.00 and set an “overweight” rating on the stock in a research note on Friday. Weiss Ratings lowered NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 2nd. JPMorgan Chase & Co. lowered NeuroPace from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $20.00 to $9.00 in a report on Friday. Finally, Mizuho assumed coverage on NeuroPace in a research note on Thursday, July 23rd. They set an “outperform” rating and a $22.00 target price for the company. Five investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, NeuroPace currently has a consensus rating of “Hold” and a consensus target price of $15.50.

NeuroPace Stock Down 37.1%

Shares of NASDAQ NPCE traded down $4.46 during midday trading on Friday, hitting $7.56. The company’s stock had a trading volume of 6,104,874 shares, compared to its average volume of 127,272. The company has a debt-to-equity ratio of 4.97, a current ratio of 4.94 and a quick ratio of 3.91. The firm has a market capitalization of $259.46 million, a price-to-earnings ratio of -13.50 and a beta of 1.98. The business’s fifty day simple moving average is $13.21 and its two-hundred day simple moving average is $14.75. NeuroPace has a 1 year low of $5.46 and a 1 year high of $19.60.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in NPCE. BlackRock Inc. purchased a new position in shares of NeuroPace in the 2nd quarter valued at about $39,369,000. First Light Asset Management LLC lifted its stake in NeuroPace by 82.3% during the first quarter. First Light Asset Management LLC now owns 2,459,966 shares of the company’s stock worth $32,349,000 after purchasing an additional 1,110,484 shares during the last quarter. Deutsche Bank AG purchased a new stake in NeuroPace during the second quarter worth approximately $14,919,000. GSA Capital Partners LLP acquired a new position in NeuroPace in the second quarter valued at approximately $1,836,000. Finally, Man Group plc acquired a new position in NeuroPace in the second quarter valued at approximately $1,336,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Latest NeuroPace News

These are some of the NPCE news items that stood out recently:

• Positive Sentiment: NeuroPace reported a Q3 loss of $0.03 per share, improved from a $0.11 loss a year earlier and better than analyst estimates. Zacks Q3 earnings report
• Negative Sentiment: The company cut its 2026 revenue outlook to $91–$92 million, well below the roughly $100.4 million consensus estimate, reinforcing concerns about its sales trajectory. Revenue miss and lowered outlook
• Negative Sentiment: Analyst actions added pressure: JPMorgan cut its rating to neutral and lowered its target from $20 to $9; Wells Fargo and Leerink Partners also downgraded the shares. KeyCorp maintained an overweight rating but cut its target from $18 to $14. Analyst rating changes

NeuroPace Company Profile

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.